Reported Earlier, Allarity Therapeutics Faces Nasdaq Delisting for Stock Price Below $1
Reported Earlier, Allarity Therapeutics Faces Nasdaq Delisting for Stock Price Below $1
On June 18, 2024, Allarity Therapeutics, Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has not complied with the Nasdaq Listing Rule 5550(a)(2) which is the requirement that for 30 consecutive business days the bid price for the Company's common stock close above the $1 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.
2024年6月18日，Allarity Therapeutics, Inc.（“公司”）收到了納斯達克股票市場有限責任公司（“納斯達克”）納斯達克上市資格工作人員（“員工”）的來信，信中表示該公司沒有遵守納斯達克上市規則5550（a）（2），該規則要求公司普通股的出價連續30個工作日收於每股1美元的最低出價要求繼續納入納斯達克資本市場。
The Company intends to request a hearing before a Nasdaq Hearings Panel (the "Panel") at which it will request continued listing pending its return to compliance. The Company's hearing request will stay the suspension of trading and delisting of the Company's common stock pending the conclusion of the hearing process. Consequently, the Company expects its common stock to remain listed on the Nasdaq Capital Market at least until the Panel renders a decision following the hearing. There can be no assurance that the Panel will grant the Company's request for a suspension of delisting or continued listing on the Nasdaq Capital Market.
該公司打算要求在納斯達克聽證小組（“小組”）舉行聽證會，要求在恢復合規之前繼續上市。在聽證程序結束之前，公司的聽證請求將暫停公司普通股的交易和退市。因此，該公司預計，至少在小組在聽證會後做出決定之前，其普通股將繼續在納斯達克資本市場上市。無法保證專家小組會批准該公司暫停除牌或繼續在納斯達克資本市場上市的請求。